Regent Peak Wealth Advisors LLC buys 460 shares of Johnson & Johnson (NYSE:JNJ)


Regent Peak Wealth Advisors LLC increased its stake in Johnson & Johnson (NYSE:JNJGet a rating) by 2.6% during the first quarter, HoldingsChannel.com reports. The company held 18,390 shares of the company after purchasing an additional 460 shares during the quarter. Johnson & Johnson accounts for about 0.9% of Regent Peak Wealth Advisors LLC’s portfolio, making the stock its 19th largest holding. Regent Peak Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $3,259,000 at the end of the last quarter.

A number of other hedge funds have also recently changed their positions in the stock. Magnolia Capital Management Ltd. increased its holding in Johnson & Johnson shares by 0.5% in the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company valued at $1,978,000 after acquiring 55 additional shares in the last quarter. Howard Financial Services LTD. increased its holding in Johnson & Johnson shares by 2.1% in the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company valued at $489,000 after acquiring 57 additional shares in the last quarter. American Financial Advisors LLC increased its stake in Johnson & Johnson by 2.1% in the first quarter. American Financial Advisors LLC now owns 2,715 shares of the company worth $481,000 after buying 57 more shares in the last quarter. Capital Investment Counsel Inc increased its stake in Johnson & Johnson by 0.8% in the fourth quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company worth $1,334,000 after buying 59 additional shares in the last quarter. Finally, Kwmg LLC increased its stake in Johnson & Johnson by 2.6% in the first quarter. Kwmg LLC now owns 2,354 shares of the company worth $417,000 after purchasing 59 additional shares in the last quarter. 68.78% of the shares are held by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news from Johnson & Johnson, CAD Robert J. Decker sold 8,462 shares of the company in a transaction that took place on Thursday, May 26. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company, valued at $2,785,140. The sale was disclosed in a legal filing with the SEC, which is available via this hyperlink. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the company in a trade that took place on Thursday, May 26. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company, valued at $2,785,140. The sale was disclosed in a legal filing with the SEC, which is available via this hyperlink. Also, VPE Kathryn E. Wengel sold 40,000 shares of the company in a transaction that took place on Friday, June 10. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company, valued at $12,336,803. Disclosure of this sale can be found here. 0.35% of the shares are held by insiders.

Johnson & Johnson Stock Performance

Shares of JNJ Stock opened at $174.52 on Friday. The company has a market capitalization of $459.23 billion, a price-earnings ratio of 25.40, a PEG ratio of 3.28 and a beta of 0.63. The company’s 50-day moving average is $175.95 and its 200-day moving average is $174.42. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt ratio of 0.39. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson (NYSE:JNJGet a rating) last released its quarterly earnings data on Tuesday, July 19. The company reported earnings per share (EPS) of $2.59 for the quarter, beating the consensus estimate of $2.57 by $0.02. The company posted revenue of $24.02 billion for the quarter, versus analyst estimates of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. Johnson & Johnson revenue increased 3.0% compared to the same quarter last year. During the same period last year, the company posted earnings per share of $2.48. On average, sell-side analysts expect Johnson & Johnson to post EPS of 10.05 for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13. The ex-dividend date is Monday, August 22. This represents an annualized dividend of $4.52 and a yield of 2.59%. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

Wall Street analysts predict growth

Several brokerages have published reports on JNJ. Credit Suisse Group raised its price target on Johnson & Johnson shares from $200.00 to $205.00 and gave the stock an “outperform” rating in a Wednesday, April 20 research note. Raymond James raised his price target on Johnson & Johnson shares from $195.00 to $196.00 and gave the stock an “outperform” rating in a Wednesday, April 20 research note. SVB Leerink reduced its price target on Johnson & Johnson shares from $200.00 to $194.00 in a Wednesday July 20 research note. Daiwa Capital Markets launched a hedge on Johnson & Johnson shares in a Wednesday, June 22 research report. They set an “outperformance” rating on the stock. Finally, Morgan Stanley raised its price target on Johnson & Johnson shares from $173.00 to $174.00 and gave the stock an “equal weight” rating in a Friday, July 8 research report. . Four analysts gave the stock a hold rating, five gave the company a buy rating and one gave the company’s stock a strong buy rating. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Company Profile

(Get a rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds own JNJ? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJGet a rating).

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.

Carol N. Valencia